350 related articles for article (PubMed ID: 30556435)
21. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.
Spain L; Julve M; Larkin J
Expert Opin Pharmacother; 2016; 17(7):1031-8. PubMed ID: 27027150
[TBL] [Abstract][Full Text] [Related]
22. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
[TBL] [Abstract][Full Text] [Related]
23. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
Richman J; Martin-Liberal J; Diem S; Larkin J
Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
[TBL] [Abstract][Full Text] [Related]
24. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
Queirolo P; Spagnolo F
Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583
[TBL] [Abstract][Full Text] [Related]
25. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
Zhou AY; Johnson DB
Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
[TBL] [Abstract][Full Text] [Related]
27. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
28. Cobimetinib and vemurafenib for the treatment of melanoma.
Boespflug A; Thomas L
Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
[TBL] [Abstract][Full Text] [Related]
29. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
[TBL] [Abstract][Full Text] [Related]
30. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy of melanoma using kinase inhibitors.
Heppt MV; Tietze JK; Graf SA; Berking C
Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
[TBL] [Abstract][Full Text] [Related]
33. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
35. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
36. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
[TBL] [Abstract][Full Text] [Related]
37. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
[TBL] [Abstract][Full Text] [Related]
38. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L; De Pas T; Pagan E; Minucci S; Catania C; Digiacomo N; Cocorocchio E; Laszlo D; Di Muzio A; Barigazzi C; Stucchi E; De Grandi L; Stucchi S; Viale G; Gelber RD; Bagnardi V; Conforti F
Semin Oncol; 2023; 50(1-2):34-39. PubMed ID: 36967333
[TBL] [Abstract][Full Text] [Related]
39. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
40. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
